Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
CommBank State of the States ranks Queensland No. 1, ending Western Australia’s lead

CommBank State of the States ranks Queensland No. 1, ending Western Australia’s lead

ReutersReuters2026/09/15 00:06
  • Commonwealth Bank analysis showed Queensland ranked No. 1 in its State of the States index for the June quarter 2026.
  • Queensland displaced Western Australia, with investment-led momentum driving the shift in the national economic leaderboard.
  • Dwelling investment rose 16.8% year-on-year, the strongest in Australia; business investment increased 9%.
  • Queensland placed in the top three on five of six indicators, supporting a broad-based outperformance signal.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Commonwealth Bank of Australia published the original content used to generate this news brief on September 15, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage